+ A

Samsung BioLogics moves into the green in 2017

Feb 01,2018
Samsung BioLogics, a biopharmaceutical unit of Korea’s top conglomerate, Samsung Group, posted an operating income last year, shifting from a loss a year earlier, the company said Wednesday.

The total reached 63 billion won ($60 million) in 2017, compared to a 30.4 billion won loss reported a year earlier, the company said in a regulatory filing.

Sales also jumped 56.1 percent on-year to 459.8 billion won for the whole of last year, the company said.

Samsung BioLogics manufactures products for pharmaceutical brands such as Bristol-Myers Squibb and Roche Holding.